Heteromeric GABAA receptor structures in positively-modulated active states
Paul S. Miller,Simonas Masiulis,Tomas Malinauskas,Abhay Kotecha,Shanlin Rao,Sreenivas Chavali,Luigi De Colibus,Els Pardon,Saad Hannan,Suzanne Scott,Zhaoyang Sun,Brandon Frenz,Gianni Klesse,Sai Li,Jonathan M. Diprose,Alistair Siebert,Robert M. Esnouf,Frank DiMaio,Stephen J. Tucker,Trevor G. Smart,Jan Steyaert,M. Madan Babu,Mark S.P. Sansom,Juha T. Huiskonen,Radu Aricescu
DOI: https://doi.org/10.1101/338343
2018-01-01
bioRxiv
Abstract:Type-A γ-aminobutyric acid (GABA A ) receptors are pentameric ligand-gated ion channels (pLGICs), typically consisting of α/β/γ subunit combinations. They are the principal mediators of inhibitory neurotransmission throughout the central nervous system and targets of major clinical drugs, such as benzodiazepines (BZDs) used to treat epilepsy, insomnia, anxiety, panic disorder and muscle spasm. However, the structures of heteromeric receptors and the molecular basis of BZD operation remain unknown. Here we report the cryo-EM structure of a human α1β3γ2 GABAAR in complex with GABA and a nanobody that acts as a novel positive allosteric modulator (PAM). The receptor subunits assume a unified quaternary activated conformation around an open pore. We also present crystal structures of engineered α5 and α5γ2 GABAAR constructs, revealing the interfacial site for allosteric modulation by BZDs, including the binding modes and the conformational impact of the potent anxiolytic and partial PAM, bretazenil, and the BZD antagonist, flumazenil. These findings provide the foundation for understanding the mechanistic basis of GABA A R activation.